FierceBiotech

Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formote

HONOLULU--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the ...
MM&M

FDA OKs Merck’s Dulera for asthma

FDA approved Merck’s Dulera, a combination inhaler, for asthma patients 12 years and older, the company announced today. Dulera consists of an inhaled corticosteroid and a long-acting beta agonist, ...
FiercePharma

FDA Approves Merck's DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol for the Treat

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA ® (mometasone furoate and formoterol fumarate dihydrate) ...
Monthly Prescribing Reference

Dulera approved for the treatment of asthma

Dulera approved for the treatment of asthma Merck announced that the FDA has approved Dulera (mometasone furoate and formoterol fumarate dihydrate) inhalation aerosol for the treatment of asthma in ...
Reuters

U.S. clears Merck lung drug as SkyePharma's stalls

LONDON, June 24 (Reuters) - Merck & Co Inc's new two-in-one respiratory drug Dulera has been approved by the U.S. Food and Drug Administration, the U.S. company said on Thursday, confirming an earlier ...
FierceBiotech

FDA Approves Merck's DULERA(R) (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol for the Treatment of As

FDA Approves Merck's DULERA(R) (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol for the Treatment of Asthma in Patients 12 Years of Age and Older WHITEHOUSE STATION, N.J., Jun ...